Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EXECUTIVE VICE PRESIDENT | February 28, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 62,323 |
Ending reported balance
After 2023-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-28 · Tax withholding · Disposed 5,438 · Balance 63,662 Row 2 · 2023-03-01 · Sale · Disposed 1,339 · Balance 62,323 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 26, 2017 Filed Apr 28, 2017 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $43.94 | $4,394.10 |
DisclosureSEC source: 0001179110-17-006289 · edgar.xml · nonDerivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,924 Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $43.94 | $8,788.00 |
DisclosureSEC source: 0001179110-17-006289 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,024 Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 3,200 | $26.70 | $85,431.36 |
DisclosureSEC source: 0001179110-17-006289 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1 | $44.96 | $44.96 |
DisclosureSEC source: 0001179110-17-003682 · edgar.xml · nonDerivative · entry 6 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,024 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $44.96 | $13,488.99 |
DisclosureSEC source: 0001179110-17-003682 · edgar.xml · nonDerivative · entry 5 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,025 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 56 | $44.96 | $2,517.96 |
DisclosureSEC source: 0001179110-17-003682 · edgar.xml · nonDerivative · entry 4 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,325 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 387 | $44.96 | $17,400.95 |
DisclosureSEC source: 0001179110-17-003682 · edgar.xml · nonDerivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,381 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,463 | $45.46 | $66,507.98 |
DisclosureSEC source: 0001179110-17-003682 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,768 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 5,085 | $45.46 | $231,164.10 |
DisclosureSEC source: 0001179110-17-003682 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,231 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 146 | $44.98 | $6,567.23 |
DisclosureSEC source: 0001179110-17-002974 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,146 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 287 | $44.69 | $12,826.03 |
DisclosureSEC source: 0001179110-17-002974 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,292 Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 92,032 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002974 · edgar.xml · derivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,032 Underlying: Common shares · 92,032 shares Expires 2027-02-16 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,678 on 2/17/2018, 30,677 on 2/17/2019, and 30,677 on 2/17/2020. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 300 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001179110-17-001902 · edgar.xml · derivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 300 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 213 | $42.75 | $9,105.75 |
DisclosureSEC source: 0001179110-17-001902 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,579 Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 300 | $25.25 | $7,573.83 |
DisclosureSEC source: 0001179110-17-001902 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.